

Measures of Outcome for Stimulant Trials (MOST)

March 25-26, 2015 Hilton Rockville Hotel and Executive Meeting Center Rockville, MD

PARTICIPANT LIST

Laurie Burke, RPh, MPH

Affiliate Associate Professor University of Maryland Pharmacy School Department of Health Research Founder LORA Group, LLC Royal Oak, Maryland

Kathleen M. Carroll, PhD

Albert E. Kent Professor of Psychiatry Director of Psychosocial Research Yale University School of Medicine West Haven, Connecticut

Redonna K. Chandler, PhD

Acting Director Division of Epidemiology Services and Preventive Research National Institute on Drug Abuse (NIDA) Bethesda, Maryland

Michael J. Detke, MD, PhD

Chief Medical Officers
Clinical Professor of Psychiatry
Embera Neurotherapeutics
Indiana University School of Medicine
Carmel, Indiana

Amy Duhig, PhD

Director, Outcomes Research Xcenda Palm Harbor, Florida

Kelly Dunn, PhD

Assistant Professor Johns Hopkins University School of Medicine Baltimore, Maryland

Elliot W. Ehrich, MD

Senior Vice President, R&D Chief Medical Officer Alkermes Waltham, Massachusetts

Daniel Falk, PhD

Health Scientist Administrator National Institute on Alcohol Abuse and Alcoholism (NIAAA) Bethesda, Maryland

Joanne Fertig, PhD

National Institute on Alcohol Abuse and Alcoholism (NIAAA) National Institutes of Health Bethesda, Maryland

Jennifer Gewandter, PhD

Research Assistant Professor University of Rochester School of Medicine and Dentistry Rochester, New York

Shwe Gyaw, MD

Medical Officer National Institute on Drug Abuse (NIDA) Division of Pharmacotherapies and Medical Consequences Bethesda, Maryland

Sharon Hertz, MD

Acting Director
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)
Food and Drug Administration (FDA)
Silver Spring, Maryland

Pamela Horn, MD

Senior Clinical Reviewer
Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Office of New Drugs (OND)
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)
Silver Spring, Maryland

Keith Isenberg, MD

Medical Director Anthem St. Louis, Missouri

Kyle Kampman, MD

Professor, Department of Psychiatry Perelman School of Medicine University of Pennsylvania Philadelphia, PA

Brian Kiluk, PhD

Assistant Professor Yale University School of Medicine New Haven, Connecticut

Shenghan Lai, MD, MPH

Professor Johns Hopkins School of Medicine Baltimore, Maryland

Shou-Hua Li, PhD

Statistician
National Institute on Drug Abuse (NIDA)
National Institutes of Health (NIH)
Bethesda, Maryland

Allison Lin, PharmD, PhD

Associate Director for Special Projects
Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Office of New Drugs (OND)
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)
Silver Spring, Maryland

Raye Z. Litten, PhD

Associate Director National Institute on Alcohol Abuse and Alcoholism (NIAAA) Bethesda, Maryland

David J. McCann, PhD

Associate Director
National Institutes of Health (NIH)
National Institute on Drug Abuse (NIDA)
Division of Pharmacotherapies and Medical Consequences of
Drug Abuse (DPMCDA)
Bethesda, Maryland

F. Gerard Moeller, MD

Professor and Director of Institute for Drug and Alcohol Studies Departments of Psychiatry, Pharmacology and Toxicology, and Neurology Virginia Commonwealth University Richmond, Virginia

Ivan Montoya, MD, MPH

Deputy Director National Institute on Drug Abuse (NIDA) Division of Pharmacotherapies and Medical Consequences of Drug Abuse (DPMCDA) Bethesda, Maryland

Kenzie Preston, PhD

National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) Baltimore, Maryland

Tanya Ramey, MD, PhD

Medical Officer National Institutes of Health (NIH) National Institute on Drug Abuse (NIDA) North Bethesda, Maryland

Rigoberto Roca, MD

Deputy Director
Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Office of New Drugs (OND)
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)
Silver Spring, Maryland

Megan Ryan, BS, MBA

Clinical Project Manager National Institute on Alcohol Abuse and Alcoholism (NIAAA) Bethesda, Maryland

Kenneth Silverman, PhD

Professor of Psychiatry & Behavioral Sciences Johns Hopkins University School of Medicine Baltimore, Maryland

Rachel Skeete, MD

Medical Officer

Food and Drug Administration (FDA)

Center for Drug Evaluation and Research (CDER)

Office of New Drugs (OND)

Division of Anesthesia, Analgesia and Addiction Products (DAAAP)

Silver Spring, Maryland

Phil Skolnick, PhD, DSc (Hon)

Director

Division of Pharmacotherapies and Medical Consequences of

Drug Abuse (DPMCDA)

National Institute on Drug Abuse (NIDA)

National Institutes of Health (NIH)

Bethesda, Maryland

Ashley F. Slagle, MS, PhD

Study Endpoint Reviewer

Center for Drug Evaluation and Research (CDER)

COA Qualification Scientific Coordinator

Food and Drug Administration (FDA)

Silver Spring, Maryland

Steven Sparenborg, PhD

Center for the Clinical Trials Network National Institute on Drug Abuse (NIDA) Rockville, Maryland

Eric C. Strain, MD

Professor

Director, Johns Hopkins Center for Substance Abuse Treatment and Research Medical Director, Behavioral Pharmacology Research Unit Johns Hopkins University School of Medicine Baltimore, Maryland

Robert L. Walsh, BS

Chief, Regulatory Affairs Branch National Institute on Drug Abuse (NIDA) Bethesda, Maryland

Constance Weisner, DrPH, MSW

Professor and Section Chief Division of Research, Kaiser Permanente Department of Psychiatry University of California, San Francisco San Francisco, California

Celia Winchell, MD

Team Leader
Food and Drug Administration (FDA)
Center for Drug Evaluation and Research (CDER)
Office of New Drugs (OND)
Division of Anesthesia, Analgesia and Addiction Products (DAAAP)
Silver Spring, Maryland

George Woody, MD

Professor, Department of Psychiatry University of Pennsylvania and Treatment Research Institute Philadelphia, PA 19106